Francis Medical Showcases Vanquish Prostate Ablation System at Major Urology Congress

A LinkedIn post from Francis Medical highlights the company’s presence at the 41st Annual European Association of Urology Congress (EAU26) in London, described as a leading European urology event. The post notes that senior leadership, including the CEO and Director of Global Commercial Marketing, is on site to engage with urologists, healthcare practitioners, and urology networks.

According to the post, Francis Medical is using the conference to showcase its 510(k)-cleared Vanquish Water Vapor Ablation System, a minimally invasive, transurethral device intended for targeted prostate tissue ablation using sterile water vapor thermal energy. The emphasis on U.S. FDA clearance and Rx-only status suggests the product is positioned for regulated clinical use, which may support credibility with specialists and potential partners.

For investors, the visibility at EAU26 points to an active commercialization and physician-education strategy in a key specialist market. If engagement at this conference translates into broader clinical adoption or distribution relationships, it could support revenue growth prospects and strengthen Francis Medical’s competitive stance in the prostate health and medtech segments.